Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 02, 2023

BUY
$6.29 - $11.01 $1,534 - $2,686
244 Added 2.4%
10,407 $85,000
Q3 2022

Oct 12, 2022

BUY
$2.94 - $11.87 $346 - $1,400
118 Added 1.17%
10,163 $78,000
Q2 2022

Jul 19, 2022

BUY
$2.13 - $5.38 $21,395 - $54,042
10,045 New
10,045 $29,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $63.9M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Sawtooth Solutions, LLC Portfolio

Follow Sawtooth Solutions, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sawtooth Solutions, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sawtooth Solutions, LLC with notifications on news.